Injectable hydrogel platform with biodegradable Dawson-type polyoxometalate and R848 for combinational photothermal-immunotherapy of cancer

Yandi Liu, Yu Yang Han, Sha Lu, Yingjiao Wu, Juan Li*, Xiaoyi Sun, Jun Yan*

*此作品的通讯作者

科研成果: 期刊稿件文章同行评审

24 引用 (Scopus)
Plum Print visual indicator of research metrics
  • Citations
    • Citation Indexes: 24
  • Captures
    • Readers: 18
see details

摘要

Photothermal therapy (PTT) is a powerful strategy for cancer treatment with minimal invasiveness but still limited by lack of long-term efficacy against tumor recurrence and toxicity concerns about the slow biodegradability of the PTT agents. Herein, an injectable hydrogel platform (R848/POM@GG) of gellan gum co-loaded with Dawson-type {P2Mo18} polyoxometalate (POM) and Toll-like receptors agonist resiquimod (R848) is developed for combinational photothermal-immunotherapy of cancer. The POM-based gellan gum hydrogel (POM@GG) exhibits high photothermal conversion efficiency (63.1%) at a safe power density of 0.3 W cm-2 and good photostability during five cycles. By further incorporation of R848, the obtained R848/POM@GG exerts synergetic photothermal-immunotherapy on solid tumors, giving a high tumor inhibition rate of 99.3% and negligible lung metastases in the breast cancer mice models. A strong antitumor immune system with significantly elevated TNF-α, IL-2, and IL-6 levels is activated by R848. Additionally, the POM clusters gradually degrade to nontoxic molybdate in the physiological environment. Overall, the injectable hydrogel platform of R848/POM@GG has great translational potential for localized antitumor treatments.

源语言英语
页(从-至)1257-1266
页数10
期刊Biomaterials Science
10
5
DOI
出版状态已出版 - 7 3月 2022
已对外发布

指纹

探究 'Injectable hydrogel platform with biodegradable Dawson-type polyoxometalate and R848 for combinational photothermal-immunotherapy of cancer' 的科研主题。它们共同构成独一无二的指纹。

引用此

Liu, Y., Han, Y. Y., Lu, S., Wu, Y., Li, J., Sun, X., & Yan, J. (2022). Injectable hydrogel platform with biodegradable Dawson-type polyoxometalate and R848 for combinational photothermal-immunotherapy of cancer. Biomaterials Science, 10(5), 1257-1266. https://doi.org/10.1039/d1bm01835c